Geron: I Think We've Seen This Movie Before

Geron reported robust Q2'25 Rytelo sales, achieving $49 million in net product revenue and a 17% increase in underlying demand, which discredits prior market concerns regarding peak market share. This strong performance, drawing parallels to AUPH's past trajectory, sets the stage for a potential stock run-up in H1'26 as the market anticipates results from the IMpactMF trial for imetelstat in myelofibrosis, expected in H2'26.

Analysis

Geron (GERN) has demonstrated robust commercial momentum for Rytelo (imetelstat) in its Q2'25 results, reporting net product revenue of $49 million driven by a 17% increase in underlying demand. This performance directly challenges and appears to dispel prevailing market concerns that the drug's market share had already peaked. The situation draws a parallel to past market misjudgments concerning Aurinia Pharmaceuticals (AUPH), suggesting a potential for sustained growth that may be currently underestimated. Looking forward, a significant catalyst is the interim readout from the IMpactMF trial, which is evaluating imetelstat in myelofibrosis. With results from this trial expected in the second half of 2026, the article posits that a run-up in the stock could materialize in the first half of 2026 as investors begin to price in expectations.

Key Decisions for Investors

• Given the strong Rytelo sales of $49 million and 17% demand growth, which directly counter peak-share concerns, investors may consider the current fundamentals supportive of existing or new long positions.
• It is critical to monitor Geron for a potential run-up in the first half of 2026, as the market starts to anticipate the pivotal IMpactMF trial results expected in the second half of the year.
• The historical parallel drawn with AUPH suggests a potential pattern of market underestimation, indicating that Geron's current valuation may not fully reflect its growth trajectory ahead of the key myelofibrosis data catalyst.